On the afternoon of August 23, Zhang Xiang, member of the Party Committee and Deputy Director of the Provincial State-owned Assets Supervision and Administration Commission, led a delegation to visit the company's Liuyang production base for research. Accompanying the delegation were Wang Fei, Deputy Director of the Policy Research and Regulations Division of the Provincial State-owned Assets Supervision and Administration Commission, Gui Shuheng, Deputy Director of the Capital Gains and Financial Supervision Division, and Chen Kegen, Second-level Researcher of the Property Rights Management Division. Cai Xinya, member of the Party Committee, Deputy General Manager, and Chairman of Xingxiang Group, Shen Fanshun, General Manager, and members of the management team participated in the research.

Director Zhang Xiang and his delegation visited the company's exhibition hall and the extraction workshop of the new production line, and engaged in in-depth discussions with the company's leaders.

At the research meeting, Cai Xinya, on behalf of the company, provided a detailed report to the research team on the company's basic situation, the opportunities and challenges it faces, as well as its "14th Five-Year Plan" development strategy.

Director Zhang Xiang affirmed the steady development and achievements of the company in recent years. Regarding the company's future development, he put forward three requirements. First, it is necessary to clarify the positioning of state-owned enterprises, and adhere to the principle of not relaxing in economic development, epidemic prevention and control, and safe production. Second, it is necessary to grasp the policies of the state and Hunan Province on promoting the rapid development of traditional Chinese medicine, seize the opportunity, focus on the main business, develop industries, and assist the industry, contributing to the high-quality development of the traditional Chinese medicine industry in our province. Third, it is necessary to deepen the reform and innovation of internal mechanisms, expand the scale of industries, optimize management levels, achieve asset securitization at an early date, and strive to build the company into a demonstrative pharmaceutical benchmark enterprise in our province, providing better services for improving people's health.